Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies

The primary objective of this study is to evaluate the safety and tolerability of **BGB-16673**, a Bruton Tyrosine Kinase-targeted protein degrader, in patients with **B-Cell Malignancies**. This is clinically relevant as it aims to determine the potential of BGB-16673 to provide a novel therapeutic option for patients with these types of cancers, which could lead to improved treatment outcomes.

The clinical trial involves a total of **418 participants** diagnosed with **B-Cell Malignancies**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not specified, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data from a diverse group, ensuring representation across different demographics within the specified age categories.

The clinical trial is designed as a **Phase 1/2**, open-label, dose-escalation and expansion study, focusing on the evaluation of a Bruton tyrosine kinase-targeted protein-degrader, BGB-16673, in patients diagnosed with **B-cell malignancies**. The trial is set to commence recruitment on September 12, 2023, with an estimated completion date of August 11, 2028. The study aims to assess the safety, tolerability, and preliminary efficacy of the investigational drug in a controlled environment. Participants will be involved in a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This initial visit will include a comprehensive assessment of the participant's medical history and current health status.

Following the inclusion visit, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participant's response to the treatment, assess any adverse effects, and adjust dosages as necessary. The frequency and number of follow-up visits will be determined by the specific protocol of the trial phase. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment. The expected length of participant involvement will vary depending on individual response and the specific phase of the trial they are enrolled in.

Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or if the investigator deems it in the participant's best interest to withdraw. The trial's design ensures that all procedures are conducted in accordance with ethical standards and regulatory requirements, prioritizing participant safety and the integrity of the data collected. The study will contribute valuable insights into the treatment of B-cell malignancies, potentially informing future therapeutic strategies.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on September 12, 2023, with an estimated completion date of August 11, 2028. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation.